CN105025904A - 用顺铂脂质复合物预防癌症的肺部复发 - Google Patents

用顺铂脂质复合物预防癌症的肺部复发 Download PDF

Info

Publication number
CN105025904A
CN105025904A CN201380045971.1A CN201380045971A CN105025904A CN 105025904 A CN105025904 A CN 105025904A CN 201380045971 A CN201380045971 A CN 201380045971A CN 105025904 A CN105025904 A CN 105025904A
Authority
CN
China
Prior art keywords
inhalation
bone
osteosarcoma
lung
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380045971.1A
Other languages
English (en)
Chinese (zh)
Inventor
F·H·安东尼
M·M·帕里斯
E·J·托马斯
章广韬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eleison Pharmaceuticals LLC
Original Assignee
Eleison Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eleison Pharmaceuticals LLC filed Critical Eleison Pharmaceuticals LLC
Priority to CN202011157925.9A priority Critical patent/CN112451486A/zh
Priority to CN202210952065.0A priority patent/CN115414384A/zh
Publication of CN105025904A publication Critical patent/CN105025904A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380045971.1A 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发 Pending CN105025904A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202011157925.9A CN112451486A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发
CN202210952065.0A CN115414384A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261743398P 2012-09-04 2012-09-04
US61/743,398 2012-09-04
PCT/US2013/058025 WO2014039533A2 (en) 2012-09-04 2013-09-04 Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202210952065.0A Division CN115414384A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发
CN202011157925.9A Division CN112451486A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发

Publications (1)

Publication Number Publication Date
CN105025904A true CN105025904A (zh) 2015-11-04

Family

ID=50187920

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202011157925.9A Pending CN112451486A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发
CN201380045971.1A Pending CN105025904A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发
CN202210952065.0A Pending CN115414384A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202011157925.9A Pending CN112451486A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210952065.0A Pending CN115414384A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发

Country Status (10)

Country Link
US (1) US11291644B2 (enExample)
EP (1) EP2892524B1 (enExample)
JP (1) JP2015530387A (enExample)
CN (3) CN112451486A (enExample)
CA (1) CA2883703C (enExample)
DK (1) DK2892524T3 (enExample)
ES (1) ES2848025T3 (enExample)
MX (1) MX2015002842A (enExample)
PL (1) PL2892524T3 (enExample)
WO (1) WO2014039533A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109568336A (zh) * 2018-12-29 2019-04-05 江苏靶标生物医药研究所有限公司 一种铂类化合物和硫酸软骨素的组合物及其应用
RU235474U1 (ru) * 2025-03-28 2025-07-03 Федеральное государственное бюджетное учреждение "Северо-западный окружной научно-клинический центр им. Л.Г. Соколова Федерального медико-биологического агентства" Имплант для повторной брахитерапии рака предстательной железы

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
WO2014039533A2 (en) 2012-09-04 2014-03-13 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
US11478504B2 (en) 2013-07-08 2022-10-25 International Dehydrated Foods, Inc. Compositions and methods for preventing/treating metabolic syndrome
US10555967B2 (en) * 2013-07-08 2020-02-11 International Dehydrated Foods, Inc. Compositions prepared from poultry and methods of their use
WO2015134627A1 (en) * 2014-03-07 2015-09-11 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch1 antibodies
JP2024509957A (ja) 2021-03-11 2024-03-05 カロサイト・インコーポレイテッド 体液から生合成ナノ粒子を取り出すための組成物および方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
CN1976711A (zh) * 2004-03-18 2007-06-06 特兰萨维股份有限公司 通过吸入给药顺铂
US20090130194A1 (en) * 2005-11-08 2009-05-21 Transave, Inc. Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously
US20090202431A1 (en) * 2005-04-08 2009-08-13 University Of Florida Research Foundation, Inc. Stem-like cells in bone sarcomas

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (enExample) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4451447A (en) 1980-03-31 1984-05-29 Bristol-Myers Company Pharmaceutical formulations
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5435989A (en) 1982-03-30 1995-07-25 Vestar, Inc. Method of targeting a specific location in a body
IT1203660B (it) 1982-10-08 1989-02-15 Glaxo Group Ltd Dispositivi per somministrare farmaci a pazienti e confezione di blister per essi
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US4981692A (en) 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
USRE33071E (en) 1983-03-28 1989-09-26 Platinum bound to transferrin for use in the treatment of breast tumors
US4590001A (en) 1983-03-28 1986-05-20 Stjernholm Rune L Platinum bound to transferrin for use in the treatment of breast tumors
US4572425A (en) 1983-08-01 1986-02-25 Russell William S Reusable container
EP0153955A1 (en) 1983-09-06 1985-09-11 Health Research, Inc. Liposome delivery method for decreasing the toxicity of an antitumor drug
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
CA1270198A (en) 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
GB2178965B (en) 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
JPH0665648B2 (ja) 1985-09-25 1994-08-24 塩野義製薬株式会社 白金系抗癌物質の安定な凍結真空乾燥製剤
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US5041581A (en) 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5117022A (en) 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5320906A (en) 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
JP2877160B2 (ja) 1987-07-29 1999-03-31 ザ リポソーム カンパニー，インコーポレイテッド 粒子のサイズによる分離方法
IL83380A (en) 1987-07-30 1991-04-15 Teva Pharma Stable aqueous cisplatin solutions
EP0331504B1 (en) 1988-03-04 1992-06-10 Takeda Chemical Industries, Ltd. Liposome composition
US5141751A (en) 1988-06-29 1992-08-25 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structures
US5077057A (en) 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
EP0551169A1 (en) 1992-01-10 1993-07-14 Takeda Chemical Industries, Ltd. Liposome composition and production thereof
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5958449A (en) 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
CN1088777A (zh) 1992-12-18 1994-07-06 丛繁滋 用于癌病灶直接给药的化疗药物制剂的制备方法
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5780054A (en) 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
AU2230497A (en) 1996-02-26 1997-09-10 Daiichi Pharmaceutical Co., Ltd. Liposome and liposome dispersion
PT910382E (pt) 1996-04-26 2003-10-31 Genaera Corp Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
EP0929293B1 (en) 1996-08-23 2003-10-22 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO1998024424A1 (en) 1996-12-03 1998-06-11 Rijksuniversiteit Utrecht Cisplatinum comprising pharmaceutical
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
NZ336381A (en) 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
WO1998033481A1 (en) 1997-02-05 1998-08-06 Pharmacia & Upjohn Company Lipid complexes and liposomes of highly insoluble platinum complexes
FR2759293B1 (fr) 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
US6630168B1 (en) 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US7348025B2 (en) 1997-09-23 2008-03-25 Research Development Foundation Small particle liposome aerosols for delivery of anticancer drugs
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
CA2248592A1 (en) 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
ES2156506B1 (es) 1998-10-14 2002-03-01 Sumitomo Chemical Co Metodo para la produccion de oxido de propileno.
IL143046A0 (en) 1998-11-12 2002-04-21 Pilkiewicz Frank G An inhalation system
US20050074499A1 (en) 1999-03-17 2005-04-07 Mitsubishi Chemical Corporation Ligand-bonded complex
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
EP1206234A4 (en) 1999-06-03 2005-06-01 Jessie L S Au METHODS AND COMPOSITIONS FOR MODULATING PROLIFERATION AND CELL DEATH
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6800437B1 (en) 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
JP2003513030A (ja) 1999-11-05 2003-04-08 シード・キャピタル・インヴェストメンツ−２・（エスシーアイ−２）・ベスローテン・フエンノートシャップ 低い水溶性および脂肪親和性を示す物質のカプセル化方法、およびこの方法により得られる製剤
JP2003515568A (ja) 1999-12-04 2003-05-07 リサーチ ディベロップメント ファンデーション 吸入療法における二酸化炭素増強
US7025988B2 (en) 2000-02-04 2006-04-11 Lipoxen Technologies Limited Liposomes
EP1267834A4 (en) 2000-03-29 2003-08-27 Aradigm Corp CATIONIC LIPOSOMES
US20030124180A1 (en) 2000-05-02 2003-07-03 Jurgen Ebert Liposomes containing active substances
US6998393B2 (en) 2000-06-23 2006-02-14 Biopharm Solutions, Inc. Aquespheres, their preparation and uses thereof
AU2001270413A1 (en) 2000-06-30 2002-01-14 Inex Pharmaceuticals Corporation Improved liposomal camptothecins and uses thereof
JP2004537501A (ja) 2001-02-01 2004-12-16 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 肺への遺伝子送達のための安定化ポリマーエアロゾル
WO2002085387A2 (en) 2001-04-23 2002-10-31 Nucryst Pharmaceuticals Corp. A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions
ES2261735T3 (es) 2001-05-18 2006-11-16 Chiron Corporation Sistema para la administracion de una formulacion de tobramicina.
US7063860B2 (en) 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US20030059375A1 (en) 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
EP1424898A4 (en) 2001-08-20 2008-04-02 Transave Inc TREATMENT OF CANCER BY INHALATION OF STABLE FORMULATIONS CONTAINING PLATINUM
CA2477982A1 (en) 2002-03-05 2003-09-18 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
JP3415131B1 (ja) 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040022842A1 (en) 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
JP2006502233A (ja) 2002-08-02 2006-01-19 トランセーブ，インク． 白金凝集物およびその製造方法
US9186322B2 (en) 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
ES2539591T3 (es) 2002-10-29 2015-07-02 Insmed Incorporated Liberación sostenida de antiinfectantes
CN100367932C (zh) 2002-11-26 2008-02-13 吉里德科学公司 借助梯度的脂质体中药物装填的方法
US20090060998A1 (en) 2004-01-14 2009-03-05 Gilead Sciences, Inc. Lipid-based dispersions useful for drug delivery
US8221739B2 (en) * 2004-04-29 2012-07-17 Botanic Oil Innovations, Inc. Method of cancer treatment
EP1755623A4 (en) 2004-05-21 2007-10-17 Transave Inc TREATMENT OF LUNG DISEASES AND BEFORE A PULMONARY DISEASE
US20060246124A1 (en) 2004-11-08 2006-11-02 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
JP2008523151A (ja) 2004-12-14 2008-07-03 トランセイブ， インク． 生理活性物質を含む脂質粒子、その調製法及び使用法
WO2007056264A2 (en) 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007064658A2 (en) 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
GR20060100144A (el) 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
MX2011012094A (es) * 2009-05-14 2012-03-26 Oatmeal Biotechnologies Group L L C Tecnologias de plataforma para enfermedades que se presentan espontaneamente.
CN102834104A (zh) 2010-02-22 2012-12-19 优势医疗公司 治疗脑的出血性病状的方法和组合物
AU2011278931A1 (en) * 2010-07-16 2013-03-07 Epeius Biotechnologies Corporation Targeted nanoparticles for cancer and other disorders
WO2014039533A2 (en) 2012-09-04 2014-03-13 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
CN1976711A (zh) * 2004-03-18 2007-06-06 特兰萨维股份有限公司 通过吸入给药顺铂
US20090202431A1 (en) * 2005-04-08 2009-08-13 University Of Florida Research Foundation, Inc. Stem-like cells in bone sarcomas
US20090130194A1 (en) * 2005-11-08 2009-05-21 Transave, Inc. Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A.J.CHOU ETAL: "Phase Ib/IIa study of sustained release lipid inhalation targeting cisplatin by inhalation in the treatment of patient with relapsed/progressive osteosarcoma metastatic to the lung", 《ASCO ANNUAL MEETING PROCEEDINGS JOURNAL OF CLINICAL ONCOLOGY》 *
SAKKADECH LIMMAHAKHUN ET AL: "Relationships between serum biomarker levels and clinical presentation of human osteocarcomas", 《ASIA PACIFIC JOURNAL OF CANCER PREVENTION》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109568336A (zh) * 2018-12-29 2019-04-05 江苏靶标生物医药研究所有限公司 一种铂类化合物和硫酸软骨素的组合物及其应用
CN109568336B (zh) * 2018-12-29 2021-10-08 江苏靶标生物医药研究所有限公司 一种铂类化合物和硫酸软骨素的组合物及其应用
RU235474U1 (ru) * 2025-03-28 2025-07-03 Федеральное государственное бюджетное учреждение "Северо-западный окружной научно-клинический центр им. Л.Г. Соколова Федерального медико-биологического агентства" Имплант для повторной брахитерапии рака предстательной железы

Also Published As

Publication number Publication date
DK2892524T3 (da) 2021-01-25
PL2892524T3 (pl) 2021-10-25
JP2015530387A (ja) 2015-10-15
EP2892524A2 (en) 2015-07-15
MX2015002842A (es) 2015-08-12
EP2892524A4 (en) 2016-07-06
US11291644B2 (en) 2022-04-05
US20140065205A1 (en) 2014-03-06
CA2883703A1 (en) 2014-03-13
HK1212593A1 (en) 2016-06-17
EP2892524B1 (en) 2020-11-25
CN115414384A (zh) 2022-12-02
CA2883703C (en) 2021-10-19
WO2014039533A2 (en) 2014-03-13
ES2848025T3 (es) 2021-08-05
CN112451486A (zh) 2021-03-09
WO2014039533A3 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
CA2883703C (en) Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
CN115087665A (zh) 用于靶向递送治疗剂的工程化血小板
Guan et al. Nanoparticles and bone microenvironment: a comprehensive review for malignant bone tumor diagnosis and treatment
ES2409755T3 (es) Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado
Bacci et al. Neoadjuvant chemotherapy for extremity osteosarcoma: preliminary results of the Rizzoli's 4th study
Li et al. Advances in bone‐targeted drug delivery systems for neoadjuvant chemotherapy for osteosarcoma
TW200413000A (en) Intrinsic repair factor producing accelerator
US20100151006A1 (en) Cancer therapy sensitizer
CN107303277B (zh) 骨靶向脂质体、其药物和制剂及其制备方法与应用
Carneiro et al. Platelet-rich plasma gel promotes regeneration of articular cartilage in knees of sheeps
Giordano et al. Nanodelivery systems face challenges and limitations in bone diseases management
Xu et al. Targeted inhibition of STAT3 (Tyr705) by xanthatin alleviates osteoarthritis progression through the NF-κB signaling pathway
JP2022064986A (ja) Ｌｌｐ２ａ－ビスホスホネート化合物を用いて骨壊死を処置する方法
WO2012121742A1 (en) Fibrin sealant (fibringluraas®) consisting of a kit of lyophilized high concentrate fribinogen intentionally enriched and preserved with fibronolysis inhibitor a1at
JP4671962B2 (ja) デフィブロチド単独又は他の抗腫瘍剤との組み合わせを含む抗腫瘍製剤
Todd et al. LiF@ SiO2 nanocapsules for controlled lithium release and osteoarthritis treatment
US20150297623A1 (en) Methods for treatment of primary cancer and cancer metastasis
WO2023062516A1 (en) 2-deoxy-d-glucose for use in disease therapy
Weber et al. Renal cell carcinoma bone metastasis: epidermal growth factor receptor targeting.
HK1212593B (en) Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
EP4108251A1 (en) Griffithsin for use in a method of preventing or treating infections with respiratory viruses
JP2024506847A (ja) がんを処置および改善するための方法
Pilat et al. Vascular targeting agents
US20120171181A1 (en) Compositions and minimally invasive methods for treating cancer
Kolarić et al. Combined cis-platinum plus radiation antitumor activity in locoregionally advanced squamous cell esophageal cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151104

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151104